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Aluminium phosphide (alp) is a very effective outdoor and indoor pesticide used for protecting stored grains from rodents and 
other pests.1 In Iran, AlP tablets are widely used for 
protecting rice against pests and so are traditionally 
called “rice tablets”.2 Phosphine gas (PH3) is rapidly 
formed and released when AlP comes into contact 
with water or dilute acids, such as those found in the 
stomach, and is the fatal active form of the pesticide.3 
The two main routes of acute toxicity due to AlP are 
the ingestion of AlP tablets and inhalation of released 
PH3. Although the exact mechanism of action of AlP 
is not clearly understood, PH3 is thought to induce 
toxicity by blocking the cytochrome c oxidase enzyme 
and inhibiting oxidative phosphorylation which event-
ually leads to myocyte death.1,2 AlP poisoning has a 
very high mortality rate (30–100%) and survival is 
unlikely if more than 1,500 mg is ingested; the lethal 
dose for an individual weighing 70 kg is 150–500 mg.1 
Exposure to AlP is rarely accidental and the majority 
of cases of severe AlP poisoning are reportedly due to 
the deliberate ingestion of AlP tablets with suicidal 
intentions.2,3 Although there are reports of accidental 
inhalation of PH3 gas, especially among workers, AlP 
is known as a suicide poison with no effective antidote 
that can be easily bought.2
Presenting features of AlP intoxication include the 
rapid onset of shock, vomiting, nausea, retrosternal 
and epigastric pain, dyspnoea, anxiety, agitation and 
garlic-odour breath.3 An early sign of AlP poisoning is 
severe metabolic acidosis and hypotension, which leads 
to shock and tissue perfusion failure in the first couple 
of hours after ingestion due to cardiogenic shock and 
peripheral circulatory failure.1–4 Other cardiovascular 
complications include cardiac arrhythmias and acute 
myocardial infarctions.1 Profound circulatory collapse 
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abstract: Aluminium phosphide (AlP) is used to protect stored grains from rodents. It produces phosphine gas 
(PH3), a mitochondrial poison thought to cause toxicity by blocking the cytochrome c oxidase enzyme and inhibiting 
oxidative phosphorylation, which results in cell death. AlP poisoning has a high mortality rate among humans due 
to the rapid onset of cardiogenic shock and metabolic acidosis, despite aggressive treatment. We report a 21-year-
old male who was referred to the Afzalipour Hospital, Kerman, Iran, in 2015 after having intentionally ingested a 3 g 
AlP tablet. He was successfully treated with crystalloid fluids, vasopressors, sodium bicarbonate, digoxin, glucagon 
and antioxidant agents and was discharged from the hospital six days after admission in good clinical condition. 
For the treatment of AlP poisoning, the combination of glucagon and digoxin with antioxidant agents should be 
considered. However, evaluation of further cases is necessary to optimise treatment protocols.
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ي�صبب  اأنه  يعتقد  �صم متقدري  الف�صفني، وهو  وينتج غاز  القوار�ض.  املخزنة من  احلبوب  االألومينيوم حلماية  فو�صفيد  ي�صتخدم  امللخ�ص: 
ال�صمية من خالل اإعاقة اأنزمي اأك�صيد c من ال�صيتوكروم و تثبيط الف�صفتة االأك�صيدية، التي توؤدي اإىل موت اخللية. ت�صمم فو�صفيد االألومينيوم 
له معدل عايل للوفاة عند الب�رض؛ نظراً ل�رضعة حدوث ال�صدمة قلبية املن�صاأ و احلما�ض االأ�صتقالبي. نعر�ض حالة لذكر عمره 21 عاما الذي 
مت حتويله اإىل م�صت�صفى اأفزاليبور، كرمن، اإيران عام 2015م بعد بلعه عمداً 3 غرامات من حبة فو�صفيد االألومينيوم، مت عالج احلالة بنجاح 
عن طريق �صوائل بلورانية وروافع التوتر الوعائي وبيكربونات ال�صوديوم والديجوك�صن و الغلوكاغون وم�صادات التاأك�صد، و مت اإخراجه من 
امل�صت�صفى بعد �صتة اأيام و هو يف و�صٍع �صحٍي جيد، لذا ينبغي اأن يوؤخذ بعني االإعتبار هذا املزيج من الغلوكاغون وديجوك�صني مع م�صادات 
التاأك�صد لعالج ت�صمم فو�صفيد االألومينيوم، كم اأنه البد من تقييم حاالت اأخرى لتح�صني �صيا�صات العالج يف مثل هذه احلاالت.
كلمات مفتاحية: فو�صفيد االألومينيوم؛ الف�صفني؛ ت�صمم؛ ديجوك�صني؛ غلوكاغون؛ م�صادات التاأك�صد؛ تقرير حالة؛ اإيران.
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is commonly associated with AlP poisoning; this is 
believed to be due to the direct effect of PH3 on the 
heart cells.5 Cardiogenic shock is one of the main 
causes of death.5,6 There is currently no known 
antidote for this poison and most treatment modalities 
are not successful; however, the effective treatment 
of AlP poisoning using an intra-aortic balloon pump 
(IABP) and digoxin has previously been reported.5,6 
In addition, other researchers have reported that 
glucagon, digoxin or antioxidants administered 
individually to poisoned patients have had a beneficial 
effect.3,5 This report is the first to present the combined 
administration of glucagon, digoxin and antioxidants 
in the management of a patient with AlP poisoning.
Case Report
A 21-year-old man was referred to the Afzalipour 
Hospital, Kerman, Iran, in 2015 after the intentional 
ingestion of a 3 g rice tablet containing AlP. The patient 
had swallowed the tablet whole with one glass of water, 
without crushing the AlP tablet into a powder. He had 
vomited approximately 45 minutes after ingesting 
the tablet and was admitted to a local hospital four 
hours later. At this point, he was completely awake 
and complained of abdominal and retrosternal pain 
and severe thirst. He had previously had a ventricular 
septal defect which had been repaired five years earlier. 
At presentation to the local hospital, the patient’s 
initial vital signs were as follows: blood pressure of 
90/60 mmHg; pulse rate of 140 beats/minute; 
respiratory rate of 18 breaths/minute; axillary temper-
ature of 36.4 °C; and oxygen saturation of 95% in 
ambient air. 
Approximately 10 hours after ingestion of the 
tablet, the patient was referred to the Afzalipour 
Hospital, the main referral toxicology centre in 
Kerman province.7 He was confused and his vital 
signs were as follows: blood pressure of 85/40 mmHg; 
pulse rate of 130 beats/minute; respiratory rate of 
16 breaths/minute; axillary temperature of 36.7 °C; 
and oxygen saturation of 93% in ambient air. Arterial 
blood gas analysis indicated that his pH, partial 
pressure of carbon dioxide, bicarbonate (HCO3) and 
Table 1: Clinical and laboratory findings of a patient with aluminium phosphide poisoning
Finding Post-admission time in hours
0 2 12 24 48 144*
Blood pressure in mmHg 85/40 90/60 98/70 100/40 120/85 110/70
Pulse rate in beats/minute 130 120 112 115 98 85
Respiratory rate in breaths/minute 16 17 18 12 14 16
Temperature in °C 36.7 36.0 37.1 37.2 36.8 37.3
O2 saturation in % 93 92 90 95 97 96
PaCO2 in mmHg 28.5 26.8 33.6 30.2 41.7 47.6
pH 7.18 7.20 7.43 7.37 7.45 7.43
HCO3 in mmol/L 11.7 11.1 22.7 17.6 29.7 32.5
BE in mmol/L -17.6 -16.7 -0.2 -5.6 5.8 8.1
Na in meq/L 135 - - 137 135 140
K in meq/L 4.6 - - 3.8 3.7 3.8
WBC 14,300 - - - - 9,200
Hct 45.3 - - - - 34.5
PT 17 - - - - 16
INR 1.6 - - - - 1.1
Blood glucose in mg/dL 133 - - 141 - 123
BUN in mg/dL 20 - - 40 - 24
Creatinine in mg/dL 1.7 - - 1.4 - 1.1
*At discharge.
O2 = oxygen; PaCO2 = partial pressure of carbon dioxide; HCO3 = bicarbonate; BE = base excess; Na = sodium; meq = milliequivalent; K = potassium; 
WBC = white blood cell count; Hct = haematocrit; PT = prothrombin time; INR = international normalised ratio; BUN = blood urea nitrogen.
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been suggested to be the inhibition of cytochrome C 
oxidase, secondary toxic myocarditis and AlP-induced 
oxidative stress that lead to pump failure and cardiac 
arrest.1 There is currently no specific antidote for AlP 
poisoning and supportive therapy is the mainstay of 
treatment for poisoned patients.3,5 
Antioxidant therapy using vitamins E and C and 
NAC may theoretically have a therapeutic role in acute 
AlP poisoning, as one of the main mechanisms of AlP-
induced toxicity is oxidative stress. Some researchers 
have suggested the use of these agents—especially 
NAC—to treat AlP poisoning.9 In the current case, 
the patient was treated successfully with vitamins E 
and C and NAC. The treatment of cardiogenic shock 
caused by AlP poisoning with digoxin and an IABP 
has been suggested for mechanical support of the 
heart in toxic myocarditis and refractory shock; this 
approach has also had positive responses.5,6 Tehrani 
et al. found that hospital stay duration and rates of 
intubation, ventilation and mortality were significantly 
lower among AlP-poisoned patients who received 
NAC in comparison to controls.9 In addition, there is 
some evidence suggesting that glucagon is useful for 
the treatment of cardiogenic shock.10,11 Glucagon is 
an antidote for β-blocker poisoning but is also used 
to treat cardiogenic shock due to verapamil and, 
sometimes, imipramine.10 It has been postulated that 
glucagon activates adenylate cyclase at a different site 
to β-adrenergic agents, resulting in an increase in cyclic 
adenosine monophosphate; this increases the calcium 
pool available for release during depolarisation and 
contractility.11,12 Glucagon can also increase heart rate 
but has no effect on arterial pressure; thus, it has been 
reportedly useful in increasing mean blood pressure 
and heart rate in amitriptyline toxicity, although it 
is still unclear whether glucagon increases blood 
pressure.13 Glucagon receptors in the ventricular 
myocardium cause its inotropic effects.14 Thus, 
glucagon is a probable antidote for AlP poisoning by 
potentially increasing blood pressure and heart rate. 
Moreover, treating cardiogenic shock with glucagon 
may result in enhanced tissue perfusion.11 A previous 
case report described the successful treatment of 
a woman with AlP poisoning in Kerman, Iran, and 
concluded that the early administration of glucagon 
to AlP-poisoned patients in refractory shock may 
be beneficial.15
In addition to routine supportive treatments, 
managing the two main hazards of toxicity—oxidative 
stress and cardiogenic shock leading to circulatory 
collapse and lactic acidosis—is essential for the 
successful treatment of AlP poisoning. For this reason, 
agents with antioxidant properties such as vitamins E 
and C and NAC were administered to the patient in the 
base excess were 7.18, 28.5 mmHg, 11.7 mmol/L 
and -17.6 mmol/L, respectively. Electrocardiography 
revealed that the patient had sinus tachycardia. Using 
bedside echocardiography, the left ventricular ejection 
fraction was 35%. Serial vital signs and laboratory 
findings over time are presented in Table 1.
The patient was prescribed 44 milliequivalents 
of sodium bicarbonate every 15 minutes until the 
metabolic acidosis was corrected. He was also given 
an intravenous infusion of normal saline and vaso- 
pressors; additionally, 1 mg of glucagon was admin-
istered intravenously every 5–10 minutes until his 
blood pressure normalised after a total of 4 mg of 
glucagon. This was followed by a 4 mg/hour slow intra-
venous infusion of glucagon. Subsequently, digoxin 
(0.5 mg initially followed by 0.25 mg every six hours 
for 24 hours and 0.25 mg daily thereafter), magnesium 
sulphate (1 g initially followed by 1 g every six hours), 
10% calcium gluconate (1 g initially followed by 1 g 
every six hours), hydrocortisone (200 mg initially 
followed by 200 mg every six hours), vitamin C 
(1,000 mg every 12 hours via slow intravenous 
infusion), vitamin E (400 units intramuscularly) and 
N-acetylcysteine (NAC; 140 mg/kg orally as a loading 
dose followed by 70 mg/kg orally every 4 hours for 
up to 17 doses) were administered. With the improv-
ement of the metabolic acidosis and stabilisation of 
the patient’s vital signs, all medications were gradually 
tapered off. The patient was discharged from the 
hospital six days after admission in good clinical 
condition and completely symptom-free. He did 
not require tracheal intubation at any point during 
admission. Repeat echocardiography at discharge rev-
ealed that the left ventricle ejection fraction was 50%.
Discussion
AlP induces oxidative stress and boosts the extra-
mitochondrial release of free oxygen radicals that 
lead to lipid peroxidation and protein denaturation 
of the cell membrane in various organs.1 PH3 inhibits 
mitochondrial cytochrome C oxidase and catalase, 
induces superoxide dismutase and reduces the 
concentration of glutathione in AlP-poisoned patients, 
which leads to the generation of superoxide radicals 
and cellular peroxides.1,2 Cellular injury subsequently 
occurs via lipid peroxidation and other oxidant 
mechanisms, such as protein denaturation of the 
cell membrane and hypoxic cell damage.8 The major 
lethal consequences of AlP ingestion (i.e. profound 
circulatory collapse) are reportedly secondary to the 
toxins generated which directly affect cardiac myocytes 
and cause fluid loss and adrenal gland damage.1,3,4 The 
main causes of cardiogenic shock in AlP poisoning have 
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current case as well as glucagon and digoxin to allow 
for better tissue perfusion. Since the sites of entrance 
and accumulation of calcium ions within the cell 
are different, glucagon and digitalis have synergistic 
inotropic effects.14 Coadministration of glucagon and 
digoxin is more effective than utilising each alone.16 Due 
to the short duration of action, prolonged continuous 
infusion of glucagon is necessary.12 Although alter- 
native therapies such as angiotensin-converting 
enzyme inhibitors, intravenous diuretics and other 
intravenous inotropes are usually safer and more 
effective in cases of acutely decompensated heart 
failure, these treatments are less effective for patients 
with AlP poisoning.5 Successful treatment in the 
current case with glucagon and digoxin suggests that 
the concurrent use of high doses of these two agents 
may be useful in the treatment of AlP poisoning; 
however, this finding needs to be confirmed by further 
studies. The patient in the present case suffered from 
late vomiting; Louriz et al. observed that vomiting is a 
common symptom of AlP poisoning and that a lack of 
vomiting is a poor prognostic factor.17 
In the present case, levels of paraoxonase 1 as 
well as the total antioxidant and total oxidant statuses 
and oxidative stress index were not evaluated. These 
are important to determine the patient’s oxidant and 
antioxidant status. Previous studies have demonstrated 
that IABPs are another excellent treatment modality 
in cases of AlP poisoning;1,6 the addition of an IABP 
to the treatment protocol used in the present case 
is recommended, especially in severe cases of AlP 
poisoning. However, it is important to bear in mind 
that IABPs are not available at all poisoning centres. 
The authors of this report recommend that other 
strong antioxidants such as superoxide dismutase and 
intracellular antioxidants like tempol should be used 
when treating cases of AlP poisoning. 
Conclusion
A combination of glucagon and digoxin with anti-
oxidant agents was used to successfully treat a patient 
with AlP poisoning. However, the clinical significance 
of this approach requires further consideration and 
evaluation in order to optimise management protocols 
for AlP poisoning.
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